Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/16/2025

Management of Alopecia Areata in Children

Treatment Approach

  • The British Journal of Dermatology recommends watchful waiting without treatment as the best initial approach for pediatric cases of alopecia areata, due to the common occurrence of spontaneous remission and significant risks associated with aggressive treatments in children 1
  • Intralesional corticosteroids are often poorly tolerated in children due to pain from injections, making them less practical in pediatric populations, according to the British Journal of Dermatology 1, 2, 3

Treatment Options

  • Topical corticosteroids are widely prescribed and represent a safer alternative, though evidence for their efficacy is limited, as reported by the British Journal of Dermatology 1
  • Contact immunotherapy is recommended as first-line treatment for extensive disease, with a strength of recommendation B II-ii, and stimulates cosmetically worthwhile regrowth in less than 50% of patients, according to the British Journal of Dermatology 2, 3
  • Many clinicians are reluctant to use contact immunotherapy in children due to concerns about aggressive treatment in this age group, as noted by the British Journal of Dermatology 1, 2, 3

Treatment to Avoid

  • Dithranol (anthralin) and minoxidil lotion are widely prescribed but lack convincing evidence of efficacy, as reported by the British Journal of Dermatology 1, 2, 3
  • Potent topical corticosteroids are safe but similarly lack strong evidence for effectiveness, according to the British Journal of Dermatology 2, 3
  • Continuous or pulsed systemic corticosteroids cannot be recommended due to potentially serious side effects and inadequate efficacy evidence, as noted by the British Journal of Dermatology 1, 2, 3
  • PUVA therapy is not recommended due to potentially serious side effects and inadequate efficacy evidence, as reported by the British Journal of Dermatology 1, 2, 3

Critical Management Principles

  • The tendency toward spontaneous remission is an important consideration that often makes observation the most appropriate choice, according to the British Journal of Dermatology 1, 2, 3
  • Intralesional steroids, while evidence-based, are often impractical in children due to poor tolerance, as noted by the British Journal of Dermatology 1, 2, 3

Treatment Options for Alopecia in Girls

Assessment and Classification

  • The British Journal of Dermatology recommends determining the type and extent of alopecia, including patchy, total, universal, or ophiasis, to guide treatment decisions 4, 5
  • Consider differential diagnoses, such as trichotillomania, tinea capitis, and systemic lupus erythematosus, to ensure accurate diagnosis 5

Treatment Algorithm Based on Extent of Hair Loss

  • For limited patchy hair loss, the British Journal of Dermatology recommends intralesional corticosteroids as first-line treatment, with 62% of patients achieving full regrowth with monthly injections 6, 5
  • For extensive patchy hair loss, contact immunotherapy is recommended as first-line treatment, with a strength of recommendation B II-ii, and stimulates cosmetically worthwhile hair regrowth in <50% of patients 6, 4
  • For alopecia totalis/universalis, contact immunotherapy is recommended as first-line treatment, with a strength of recommendation C, although response rate is low 4, 7

Special Considerations

  • The British Journal of Dermatology notes that intralesional corticosteroids are often poorly tolerated in children, and many clinicians are reluctant to use aggressive treatments like contact immunotherapy in children 6, 7
  • Psychological support is crucial for patients with alopecia, particularly adolescents, to address anxiety, depression, and social difficulties 4

Treatment Pitfalls and Caveats

  • The British Journal of Dermatology warns that no treatment has been shown to alter the long-term course of alopecia areata, and patients should be warned about possible relapse during or following initially successful treatment 6, 5
  • Treatments with inadequate evidence of efficacy, such as oral zinc and isoprinosine, should be avoided, and continuous or pulsed systemic corticosteroids and PUVA are not recommended due to potentially serious side effects 6, 7